Component-resolved in vitro diagnosis of hazelnut allergy in Europe

Kirsten Skamstrup Hansen; Barbara K Ballmer-Weber; Joaquin Sastre; Jonas Lidholm; Kerstin Andersson; Hubert Oberhofer; Magdalena Lluch-Bernal; Jonas Ostling; Lars Mattsson; Frauke Schocker; Stefan Vieths; Lars K Poulsen

doi:10.1016/j.jaci.2009.02.005

Component-resolved in vitro diagnosis of hazelnut allergy in Europe

Kirsten Skamstrup Hansen, Barbara K Ballmer-Weber, Joaquin Sastre, Jonas Lidholm, Kerstin Andersson, Hubert Oberhofer, Magdalena Lluch-Bernal, Jonas Ostling, Lars Mattsson, Frauke Schocker, Stefan Vieths, Lars K Poulsen

123 Citations (Scopus)

Abstract

BACKGROUND: Food allergy to hazelnut occurs both with and without concomitant pollen allergy. OBJECTIVE: We sought to evaluate a panel of hazelnut allergens for diagnosis of hazelnut allergy in Spain, Switzerland, and Denmark. METHODS: Fifty-two patients with a positive double-blind, placebo-controlled food challenge result with hazelnuts; 5 patients with a history of anaphylaxis; 62 patients with pollen allergy but hazelnut tolerance; and 63 nonatopic control subjects were included. Serum IgE levels to hazelnut extract, recombinant hazelnut allergens (rCor a 1.04, rCor a 2, rCor a 8, rCor a 11), and native allergens (nCor a 9, nCor a Bd8K, nCor a Bd11K) were analyzed by means of ImmunoCAP. RESULTS: Among patients with hazelnut allergy, 91% (Switzerland/Spain, 100%; Denmark, 75%) had IgE to hazelnut extract, 75% to rCor a 1.04, 42% to rCor a 2, 28% to rCor a 8, and 2% to rCor a 11. The highest rate of sensitization to Cor a 1.04 was found in the northern regions (Switzerland/Denmark, 100%; Spain, 18%), whereas IgE to the lipid transfer protein rCor a 8 prevailed in Spain (Spain, 71%; Switzerland, 15%; Denmark, 5%). IgE to profilin rCor a 2 was equally distributed (40% to 45%). Among control subjects with pollen allergy, 61% had IgE to hazelnut extract, 69% to rCor a 1.04, 34% to rCor a 2, 10% to rCor a 8, and 6% to rCor a 11. CONCLUSION: Component-resolved in vitro analyses revealed substantial differences in IgE profiles of hazelnut allergic and hazelnut tolerant patients across Europe.

Original language	English
Journal	Journal of Allergy and Clinical Immunology
Volume	123
Issue number	5
Pages (from-to)	1134-41, 1141.e1-3
Number of pages	8
ISSN	0091-6749
DOIs	https://doi.org/10.1016/j.jaci.2009.02.005
Publication status	Published - 2009

Access to Document

10.1016/j.jaci.2009.02.005

Cite this

Hansen, K. S., Ballmer-Weber, B. K., Sastre, J., Lidholm, J., Andersson, K., Oberhofer, H., Lluch-Bernal, M., Ostling, J., Mattsson, L., Schocker, F., Vieths, S., & Poulsen, L. K. (2009). Component-resolved in vitro diagnosis of hazelnut allergy in Europe. Journal of Allergy and Clinical Immunology, 123(5), 1134-41, 1141.e1-3. https://doi.org/10.1016/j.jaci.2009.02.005

@article{debdf7c0785111df928f000ea68e967b,

title = "Component-resolved in vitro diagnosis of hazelnut allergy in Europe",

abstract = "BACKGROUND: Food allergy to hazelnut occurs both with and without concomitant pollen allergy. OBJECTIVE: We sought to evaluate a panel of hazelnut allergens for diagnosis of hazelnut allergy in Spain, Switzerland, and Denmark. METHODS: Fifty-two patients with a positive double-blind, placebo-controlled food challenge result with hazelnuts; 5 patients with a history of anaphylaxis; 62 patients with pollen allergy but hazelnut tolerance; and 63 nonatopic control subjects were included. Serum IgE levels to hazelnut extract, recombinant hazelnut allergens (rCor a 1.04, rCor a 2, rCor a 8, rCor a 11), and native allergens (nCor a 9, nCor a Bd8K, nCor a Bd11K) were analyzed by means of ImmunoCAP. RESULTS: Among patients with hazelnut allergy, 91% (Switzerland/Spain, 100%; Denmark, 75%) had IgE to hazelnut extract, 75% to rCor a 1.04, 42% to rCor a 2, 28% to rCor a 8, and 2% to rCor a 11. The highest rate of sensitization to Cor a 1.04 was found in the northern regions (Switzerland/Denmark, 100%; Spain, 18%), whereas IgE to the lipid transfer protein rCor a 8 prevailed in Spain (Spain, 71%; Switzerland, 15%; Denmark, 5%). IgE to profilin rCor a 2 was equally distributed (40% to 45%). Among control subjects with pollen allergy, 61% had IgE to hazelnut extract, 69% to rCor a 1.04, 34% to rCor a 2, 10% to rCor a 8, and 6% to rCor a 11. CONCLUSION: Component-resolved in vitro analyses revealed substantial differences in IgE profiles of hazelnut allergic and hazelnut tolerant patients across Europe.",

author = "Hansen, {Kirsten Skamstrup} and Ballmer-Weber, {Barbara K} and Joaquin Sastre and Jonas Lidholm and Kerstin Andersson and Hubert Oberhofer and Magdalena Lluch-Bernal and Jonas Ostling and Lars Mattsson and Frauke Schocker and Stefan Vieths and Poulsen, {Lars K}",

note = "Keywords: Adolescent; Adult; Allergens; Anaphylaxis; Corylus; Denmark; Female; Humans; Immunoglobulin E; Male; Middle Aged; Nut Hypersensitivity; Recombinant Proteins; Rhinitis, Allergic, Seasonal; Sensitivity and Specificity; Spain; Switzerland; Young Adult",

year = "2009",

doi = "10.1016/j.jaci.2009.02.005",

language = "English",

volume = "123",

pages = "1134--41, 1141.e1--3",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "5",

}

TY - JOUR

T1 - Component-resolved in vitro diagnosis of hazelnut allergy in Europe

AU - Hansen, Kirsten Skamstrup

AU - Ballmer-Weber, Barbara K

AU - Sastre, Joaquin

AU - Lidholm, Jonas

AU - Andersson, Kerstin

AU - Oberhofer, Hubert

AU - Lluch-Bernal, Magdalena

AU - Ostling, Jonas

AU - Mattsson, Lars

AU - Schocker, Frauke

AU - Vieths, Stefan

AU - Poulsen, Lars K

N1 - Keywords: Adolescent; Adult; Allergens; Anaphylaxis; Corylus; Denmark; Female; Humans; Immunoglobulin E; Male; Middle Aged; Nut Hypersensitivity; Recombinant Proteins; Rhinitis, Allergic, Seasonal; Sensitivity and Specificity; Spain; Switzerland; Young Adult

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Food allergy to hazelnut occurs both with and without concomitant pollen allergy. OBJECTIVE: We sought to evaluate a panel of hazelnut allergens for diagnosis of hazelnut allergy in Spain, Switzerland, and Denmark. METHODS: Fifty-two patients with a positive double-blind, placebo-controlled food challenge result with hazelnuts; 5 patients with a history of anaphylaxis; 62 patients with pollen allergy but hazelnut tolerance; and 63 nonatopic control subjects were included. Serum IgE levels to hazelnut extract, recombinant hazelnut allergens (rCor a 1.04, rCor a 2, rCor a 8, rCor a 11), and native allergens (nCor a 9, nCor a Bd8K, nCor a Bd11K) were analyzed by means of ImmunoCAP. RESULTS: Among patients with hazelnut allergy, 91% (Switzerland/Spain, 100%; Denmark, 75%) had IgE to hazelnut extract, 75% to rCor a 1.04, 42% to rCor a 2, 28% to rCor a 8, and 2% to rCor a 11. The highest rate of sensitization to Cor a 1.04 was found in the northern regions (Switzerland/Denmark, 100%; Spain, 18%), whereas IgE to the lipid transfer protein rCor a 8 prevailed in Spain (Spain, 71%; Switzerland, 15%; Denmark, 5%). IgE to profilin rCor a 2 was equally distributed (40% to 45%). Among control subjects with pollen allergy, 61% had IgE to hazelnut extract, 69% to rCor a 1.04, 34% to rCor a 2, 10% to rCor a 8, and 6% to rCor a 11. CONCLUSION: Component-resolved in vitro analyses revealed substantial differences in IgE profiles of hazelnut allergic and hazelnut tolerant patients across Europe.

AB - BACKGROUND: Food allergy to hazelnut occurs both with and without concomitant pollen allergy. OBJECTIVE: We sought to evaluate a panel of hazelnut allergens for diagnosis of hazelnut allergy in Spain, Switzerland, and Denmark. METHODS: Fifty-two patients with a positive double-blind, placebo-controlled food challenge result with hazelnuts; 5 patients with a history of anaphylaxis; 62 patients with pollen allergy but hazelnut tolerance; and 63 nonatopic control subjects were included. Serum IgE levels to hazelnut extract, recombinant hazelnut allergens (rCor a 1.04, rCor a 2, rCor a 8, rCor a 11), and native allergens (nCor a 9, nCor a Bd8K, nCor a Bd11K) were analyzed by means of ImmunoCAP. RESULTS: Among patients with hazelnut allergy, 91% (Switzerland/Spain, 100%; Denmark, 75%) had IgE to hazelnut extract, 75% to rCor a 1.04, 42% to rCor a 2, 28% to rCor a 8, and 2% to rCor a 11. The highest rate of sensitization to Cor a 1.04 was found in the northern regions (Switzerland/Denmark, 100%; Spain, 18%), whereas IgE to the lipid transfer protein rCor a 8 prevailed in Spain (Spain, 71%; Switzerland, 15%; Denmark, 5%). IgE to profilin rCor a 2 was equally distributed (40% to 45%). Among control subjects with pollen allergy, 61% had IgE to hazelnut extract, 69% to rCor a 1.04, 34% to rCor a 2, 10% to rCor a 8, and 6% to rCor a 11. CONCLUSION: Component-resolved in vitro analyses revealed substantial differences in IgE profiles of hazelnut allergic and hazelnut tolerant patients across Europe.

U2 - 10.1016/j.jaci.2009.02.005

DO - 10.1016/j.jaci.2009.02.005

M3 - Journal article

C2 - 19344939

SN - 0091-6749

VL - 123

SP - 1134-41, 1141.e1-3

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 5

ER -

Component-resolved in vitro diagnosis of hazelnut allergy in Europe

Abstract

Access to Document

Fingerprint

Cite this